Cellular Senescence: The Aging Cell and Its Impact on Tissue Function
- Cellular senescence is a state of permanent cell cycle arrest , the cell stops dividing but remains metabolically active.
- Senescent cells accumulate with age in every tissue. They secrete inflammatory factors (the SASP , senescence-associated secretory phenotype) that damage neighboring cells.
- The accumulation of senescent cells contributes to tissue aging, chronic inflammation, and age related diseases including atherosclerosis, osteoarthritis, and neurodegeneration.
- Senolytics are drugs that selectively kill senescent cells. The D+Q combination (dasatinib + quercetin) has shown promise in early human trials, but long term safety data is absent.
- Exercise and caloric restriction reduce senescent cell burden without drugs.
What a senescent cell is
A senescent cell has permanently exited the cell cycle. It will never divide again. But it does not die. It sits in tissue, metabolically active, secreting a cocktail of inflammatory cytokines, growth factors, and matrix-degrading enzymes. This secretion profile , the senescence-associated secretory phenotype, or SASP , is what makes senescent cells harmful.
The SASP includes IL-6, IL-8, TNF-alpha, matrix metalloproteinases, and chemokines. These factors degrade the extracellular matrix, promote local inflammation, and can even induce senescence in neighboring cells through paracrine signaling. A small number of senescent cells can damage a much larger volume of tissue.
Triggers for senescence include:
- Telomere shortening (replicative senescence , the Hayflick limit)
- DNA damage (from radiation, oxidative stress, chemotherapy)
- Oncogene activation (a tumor-suppressive mechanism , better senescent than cancerous)
- Epigenetic changes and chromatin disruption
The Double-Edged Sword
Senescence is not a mistake. It is a cancer-protection mechanism that becomes pathogenic when senescent cells accumulate faster than the immune system clears them. In youth, senescent cells appear and are quickly removed by NK cells and macrophages. With age, immune clearance slows, and senescent cells accumulate. The system that protects you from cancer in early life contributes to tissue aging in later life.
Where senescent cells accumulate and what they do
Senescent cells have been found in virtually every aged tissue:
Skin. Senescent fibroblasts and keratinocytes produce matrix metalloproteinases that degrade collagen. This contributes to wrinkle formation and loss of elasticity. UV exposure accelerates senescence in skin , photoaging and biological aging converge on the same cellular endpoint.
Bone and cartilage. Senescent cells in joints drive osteoarthritis by secreting inflammatory factors and enzymes that degrade cartilage. Removing senescent cells in mouse models of osteoarthritis reduces joint degeneration and pain.
Vasculature. Senescent endothelial cells and vascular smooth muscle cells contribute to atherosclerosis. They promote plaque instability by secreting proteases and inflammatory signals. Senolytic treatment reduces atherosclerotic plaque burden in mouse models.
Brain. Senescent astrocytes and microglia accumulate with age and in neurodegenerative disease. Their SASP promotes neuroinflammation. Clearance of senescent glial cells in mouse models reduces tau pathology and cognitive decline.
Fat tissue. Senescent preadipocytes impair insulin sensitivity and promote metabolic inflammation. This is one mechanism linking obesity and aging , excess adipose tissue harbors more senescent cells.
Senescent Cell Impact
A senescent cell makes up perhaps 1–5% of cells in aged tissue. But that small fraction, through SASP secretion, can functionally impair a much larger volume of surrounding tissue. Removing them produces benefits disproportionate to their numbers , a pattern consistent in animal studies across multiple disease models.
Senolytics: killing zombie cells
Senolytics are drugs that selectively induce apoptosis in senescent cells while leaving normal cells alone. They exploit the fact that senescent cells upregulate pro-survival pathways (anti-apoptotic BCL-2 family proteins) to resist their own death signals. Senolytics block these pathways, tipping senescent cells into apoptosis.
Dasatinib + Quercetin (D+Q). The most studied senolytic combination. Dasatinib is a tyrosine kinase inhibitor (approved for leukemia). Quercetin is a plant flavonoid. Together they clear senescent cells in mice and improve cardiac function, bone density, and lifespan. The first human trial (2019) in idiopathic pulmonary fibrosis patients showed improved physical function, though the study was small (14 patients). Larger trials are ongoing.
Fisetin. A flavonoid found in strawberries and apples. It has senolytic activity in cell and animal models. Human data is limited to a handful of small trials, mostly measuring senescent cell markers rather than clinical outcomes. Fisetin is widely available as a supplement, but the doses used in animal studies (equivalent to grams in humans) are far higher than what a diet provides.
Navitoclax. A BCL-2 inhibitor that potently clears senescent cells but also kills platelets, causing thrombocytopenia. This side effect has limited its development.
The senolytic field is moving fast. As of 2026, multiple phase 2 trials are running. But the drugs are not ready for healthy-aging use. long term safety , particularly the risk of impairing wound healing and tissue repair, which require transient senescence , is unknown. Intermittent dosing (e.g., once monthly) is being tested to balance senescent cell clearance against repair function.
Non-drug approaches
Exercise. Regular physical activity reduces senescent cell markers in muscle and adipose tissue. The mechanism likely involves improved immune surveillance (exercise mobilizes NK cells), reduced oxidative stress (which triggers senescence), and AMPK activation (which promotes autophagy of damaged cellular components).
Caloric restriction. long term caloric restriction reduces senescent cell burden across multiple tissues in animal models. The CALERIE trial in humans showed that two years of moderate caloric restriction improved multiple aging biomarkers, though senescent cell burden was not directly measured.
Fasting and intermittent fasting. Nutrient deprivation suppresses mTOR and insulin/IGF-1 signaling, both of which promote senescence when chronically active. Fasting also triggers autophagy, which clears the damaged organelles and proteins that can trigger senescence.
Conclusion
Senescent cells accumulate with age and damage tissue through inflammatory secretions. Removing them , with drugs or lifestyle , improves healthspan in every animal model tested. The senolytic drug pipeline is real and accelerating, but current compounds lack long term human safety data. In the meantime, exercise, caloric moderation, and intermittent fasting reduce senescent cell burden through pathways that are well-characterized and carry no risk of thrombocytopenia. The drugs will improve. Until they do, the non-drug approaches work now.
References
[1] Campisi J. “Aging, cellular senescence, and cancer.” Annu Rev Physiol. 2013;75:685-705.